Phase 2
Completed N=22
Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS
Multiple Sclerosis, Relapsing-Remitting
Source: ClinicalTrials.gov NCT02410200 ↗
Enrolled (actual)
22
Serious AEs
22.7%
Results posted
Apr 2017
Primary outcomePrimary: Change in the Number of New or Newly Enlarging T2 Hyperintense Lesions on Brain Magnetic Resonance Imaging (MRI) Scans From the Baseline Period to On-Treatment Assessment Period — -7.9 lesions — p=0.0090
Summary
The primary objective of this study is to evaluate the effect of BG00012 (dimethyl fumarate) on brain magnetic resonance imaging (MRI) lesions in pediatric participants with relapsing-remitting multiple sclerosis (RRMS). The secondary objectives of this study are to characterize the pharmacokinetics of BG00012 in pediatric participants with RRMS and to evaluate the safety and tolerability of BG00012 in pediatric participants with RRMS.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in the Number of New or Newly Enlarging T2 Hyperintense Lesions on Brain Magnetic Resonance Imaging (MRI) Scans From the Baseline Period to On-Treatment Assessment Period |
-7.9 | 0.0090 sig |
| SECONDARY Maximum Observed Plasma Concentration (Cmax) |
1998.62 | — |
| SECONDARY Time to Reach Maximum Observed Plasma Concentration (Tmax) |
4.20 | — |
| SECONDARY Apparent Clearance (CL/F) |
74.45 | — |
| SECONDARY Apparent Volume of Distribution (V/F) |
98.19 | — |
| SECONDARY Half-Life Lambda z |
0.84 | — |
| SECONDARY Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) |
3630.52 | — |
| SECONDARY Number of Participants Who Experienced Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) |
20; 7; 1; 16; 5; 0 | — |
Eligibility Criteria
Key Inclusion Criteria
- Ability of parents or legal guardians to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information in accordance with national and local subject privacy regulations. Subjects will provide assent in addition to the parent or legal guardian, as appropriate, as per local regulations.
- Must have a body weight of ≥30 kg at Screening and Day 1.
- Must have a diagnosis of RRMS according to McDonald criteria for MS (2010) [Polman 2011] and International Pediatric Multiple Sclerosis (MS) Study Group criteria for pediatric MS (2013) [Krupp 2013].
Key Exclusion Criteria
- Primary progressive, secondary progressive, or progressive relapsing MS (as defined by [Lublin and Reingold 1996]). These conditions require the presence of continuous clinical disease worsening over a period of at least 3 months. Subjects with these conditions may also have superimposed relapses but are distinguished from relapsing-remitting subjects by the lack of clinically stable periods or clinical improvement.
- Disorders mimicking MS, such as other demyelinating disorders (e.g., acute disseminated encephalomyelitis), systemic autoimmune disorders (e.g., Sjögren disease, lupus erythematosus, and neuromyelitis optica), metabolic disorders (e.g., dystrophies), and infectious disorders.
- History of severe allergic or anaphylactic reactions or known drug hypersensitivity to dimethyl fumarate or fumaric acid esters.
NOTE: Other protocol-defined inclusion/exclusion criteria may apply.
Data sourced from ClinicalTrials.gov (NCT02410200). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.